OPTIMARK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OPTIMARK (OPTIMARK).
Gadolinium-based MRI contrast agent that increases signal intensity by shortening T1 relaxation time in tissues where it accumulates.
| Metabolism | Not metabolized; eliminated primarily by glomerular filtration as unchanged drug. |
| Excretion | Primarily renal excretion (glomerular filtration). >95% of the administered dose is eliminated unchanged in urine within 24 hours. Biliary/fecal elimination is negligible (<1%). |
| Half-life | Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. In patients with severely impaired renal function (GFR <30 mL/min), half-life is significantly prolonged (up to 20 hours). |
| Protein binding | Negligible protein binding (<1%). |
| Volume of Distribution | Approximately 0.2–0.3 L/kg, indicating distribution primarily in extracellular fluid, consistent with a low molecular weight hydrophilic compound. |
| Bioavailability | Only administered intravenously; thus, bioavailability is 100% by the IV route. No other routes are clinically relevant. |
| Onset of Action | Intravenous administration: Enhancement of magnetic resonance images occurs within minutes, with peak enhancement typically achieved immediately after injection. |
| Duration of Action | Diagnostic contrast enhancement lasts approximately 45 minutes to 1 hour, sufficient for completion of MR imaging. The agent is rapidly cleared, and enhancement diminishes as the contrast is excreted. |
0.1 mmol/kg (0.2 mL/kg) intravenously as a single bolus injection; not to exceed 20 mL per dose.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR < 30 mL/min/1.73 m²: avoid use if possible; if essential, administer lowest necessary dose and do not repeat for at least 7 days. |
| Liver impairment | No specific Child-Pugh based dose adjustment required. |
| Pediatric use | Children ≥2 years: 0.1 mmol/kg (0.2 mL/kg) IV; maximum 20 mL. Neonates and infants: data insufficient. |
| Geriatric use | No specific dose adjustment; consider renal function and use lowest effective dose due to higher risk of nephrogenic systemic fibrosis. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OPTIMARK (OPTIMARK).
| Breastfeeding | Gadoversetamide is excreted in human breast milk in very small amounts (estimated <0.01% of maternal dose). The milk-to-plasma ratio is unknown. Because of rapid elimination and low oral bioavailability, risk to the nursing infant is considered negligible. The American College of Radiology recommends that breastfeeding may be continued without interruption, but the mother may choose to pump and discard milk for 12-24 hours post-contrast. |
| Teratogenic Risk | Gadoversetamide (OPTIMARK) crosses the placenta and is classified as FDA Pregnancy Category C. Animal studies have shown fetal harm, but no adequate human studies exist. In the first trimester, gadolinium-based contrast agents are associated with increased risk of congenital anomalies; use only if clearly needed. In second and third trimesters, gadolinium accumulates in amniotic fluid, with theoretical risk of nephrogenic systemic fibrosis (NSF) in the fetus; benefit must outweigh risk. |
■ FDA Black Box Warning
Nephrogenic systemic fibrosis (NSF) occurs in patients with acute or chronic severe renal insufficiency (GFR <30 mL/min/1.73m²) or acute kidney injury. These patients are at risk for NSF, a potentially fatal disease characterized by fibrosis of skin, muscles, and internal organs.
| Common Effects | Nausea Vomiting Dizziness Headache Insomnia difficulty in sleeping Itching Vaginal inflammation Diarrhea |
| Serious Effects |
History of hypersensitivity to gadoversetamide or any component of the formulation; acute or chronic severe renal insufficiency (GFR <30 mL/min/1.73m²) due to risk of NSF; acute kidney injury.
| Precautions | Risk of NSF in patients with chronic severe kidney disease or acute kidney injury; hypersensitivity reactions including anaphylaxis; acute kidney injury requiring dialysis in patients with pre-existing renal impairment; gadolinium retention for months to years in brain, bone, skin, and other tissues; fetal harm in pregnancy; adjust dose in renal impairment. |
Loading safety data…
| Fetal Monitoring | Monitor fetal heart rate and uterine activity during administration if pregnancy is known or suspected. Assess maternal renal function prior to use (eGFR >30 mL/min/1.73 m² is preferred). Evaluate for signs of acute allergic reaction. Post-procedure, monitor the neonate for any potential effects if exposure occurred close to delivery. |
| Fertility Effects | Animal studies have shown no significant impairment of fertility at clinical doses. Gadoversetamide has not been reported to affect human reproductive function. Theoretical concern for ovarian toxicity from free gadolinium ions is not substantiated at diagnostic doses. |